Five innovative companies-selected for BIO-X accelerate program

Five innovative companies selected for BIO-X accelerate program to drive impact in life science and healthcare

After a rigorous two step evaluation process the BIO-X Accelerate program, organized by STUNS Life science, five innovative companies from the East Middle Sweden region has been selected by an external Advisory Board to receive financial support. The chosen companies – ArgusEye (Linköping), Rarity Bioscience, Readily Diagnostics, Phenaros Pharmaceuticals, and Strike Pharma (all Uppsala-based) – will embark on a two-year journey to validate their groundbreaking solutions in the life science and healthcare sectors.

”With the new participants, we look forward to continuing to drive innovation in life science and health, and contribute to a sustainable and digital transformation.”

– Dajana Ilic Susak, Project Manager for the BIO-X Accelerate program at STUNS.

The program offers up to 10 million SEK in funding per project. Each company is leveraging funding and support to enhance their technologies, aiming for regulatory approvals and strategic partnerships to revolutionize the industry as well as patient care and treatment.